Stay tuned and follow the latest developments and news in Molecular Oncology.
ASCO 2025 Genekor’s Online Publications
Genekor is excited to invite you to go through our 7 online publications at this year’s ASCO meeting in May 30 – June 3, 2025, Chicago, Illinois.
Molecular profiling using NGS in lung cancer patients: Revolutionizing targeted therapy and personalized treatment.
https://meetings.asco.org/abstracts-presentations/251937
“Molecular profiling data from 4,088 NSCLC patients highlight the importance of comprehensive multigene analysis to ensure patients can benefit from available targeted therapies.”
Multigene NGS assay for biomarker identification in 621 colorectal cancer cases.
https://meetings.asco.org/abstracts-presentations/250576
“The results emphasize the pivotal role of NGS in guiding treatment decisions, including therapy stratification and the identification of hereditary CRC syndromes.”
Detection of ESR1 and PIK3CA actionable mutations in breast cancer using liquid biopsy: A step toward precision medicine
https://meetings.asco.org/abstracts-presentations/249211
“Detection of ESR1 and PIK3CA mutations supports precision oncology in breast cancer, guiding on-label therapy and revealing resistance to endocrine treatment. ctDNA analysis via liquid biopsy offers a sensitive, non-invasive tool for real-time treatment adjustments, marking a key advance in personalized cancer care.”
Analytical validation of a 1021-gene NGS panel for comprehensive tumor profiling in FFPE and liquid biopsy samples.
https://meetings.asco.org/abstracts-presentations/247571
“The 1021-gene NGS panel demonstrated high sensitivity, specificity, and reproducibility, proving its reliability for clinical molecular profiling. Its use on both FFPE and liquid biopsy samples expands its utility, especially when tissue is limited.”
Older-onset hereditary breast and ovarian cancer (HBOC) syndrome patients and clinical value of germline multigene testing.
https://meetings.asco.org/abstracts-presentations/244692
“The results of this study provide some evidence that the mutational landscape among young-onset BC patients is not different from those of older-onset BC patients, even when taking FH into account.”
Evaluation of a 1021-gene NGS panel for HRD detection in clinical samples.
https://meetings.asco.org/abstracts-presentations/244037
“The new NGS method for HRD detection showed strong concordance with established HRD assays, accurate BRCA mutation detection, and high reproducibility, supporting its clinical value in guiding PARP inhibitor therapy.”
Performance of a 52-gene NGS panel combined with shallow WGS for accurate HRD analysis.
https://meetings.asco.org/abstracts-presentations/244040
“The assay showed strong performance in identifying HRD-related genomic signatures, with 95% concordance to the validated test, supporting its clinical applicability and reliability through integration of shallow WGS.”
Genekor’s scientific team is focused on designing informative publications to share insights with the medical community and help validate trials and innovations. The goal is to advance knowledge and contribute to scientific progress through real-world applications.
For more information please contact our International Medical Manager:
George Kapetsis: g.kapetsis@genekor.com